Visual acuitychange in logMAR visual acuity, may be reported as ETDRS · retinitis pigmentosa
It is very uncertain whether vitamin A and fish oils (docosahexaenoic acid) changes visual acuitychange in logMAR visual acuity, may be reported as ETDRS compared with placebo, vitamins (including vitamin A), or no therapy (very low certainty).
1 finding from 1 review
Electroretinography (ERG) · retinitis pigmentosa
1 finding from 1 review
Optical coherence tomography (OCT) · retinitis pigmentosa
1 finding from 1 review
Adverse effects: as reported by studies · retinitis pigmentosa
1 finding from 1 review
Overall survival (baseline risks for low‐ and high‐risk groups in the control arm were estimated at 1 year) · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in overall survival (baseline risks for low‐ and high‐risk groups in… compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
1‐Year survival rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in 1‐year survival rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Response rate · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in response rate compared with cisplatin chemotherapy (high certainty).
1 finding from 1 review
Adverse events: neurotoxicity (grade 3/4) ( · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV neurotoxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Safety (AE, adverse drug reaction): thrombocytopenia Grades 3 or 4 according to National Cancer Institute · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin probably leads to higher grade III or IV thrombocytopenia compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Grade III or IV renal toxicity · combination with third‐generation drugs for advanced non‐small cell lung cancer
Carboplatin showed no clear difference in grade III or IV renal toxicity compared with cisplatin chemotherapy (moderate certainty).
1 finding from 1 review
Global state: Average endpoint score CGAS (high score = good) · Adolescents with psychosis
1 finding from 1 review
Mental State: Mean end point score PANSS ‐ (high score = good) · Adolescents with psychosis
1 finding from 1 review
Cognitive functioning: Attaining normal cognitive functioning ‐ Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global functioning: Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: Not reported · Adolescents with psychosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Service use: Number of participants needing admission · Adolescents with psychosis
PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) showed no clear difference in service use: Number of participants needing admission compared with NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term) (low certainty).
1 finding from 1 review
Leaving the study early · Adolescents with psychosis
PSYCHOEDUCATIONAL (PE) + MULTIFAMILY TREATMENT (MFT) showed no clear difference in leaving the study early: For any reason compared with NONSTRUCTURED GROUP THERAPY (NSGT, all long‐term) (low certainty).
1 finding from 1 review
Transplant or graft survival · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes transplant or graft survival compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
Delayed graft function · pre‐existing and new‐onset diabetes in kidney transplant recipients
It is very uncertain whether more intensive changes delayed graft function Time frame: 1 to 3 years compared with less intensive insulin therapy (very low certainty).
1 finding from 1 review
HbA1c (%) · pre‐existing and new‐onset diabetes in kidney transplant recipients
1 finding from 1 review